Schulze-Neick, I. and Hartenstein, P. and Li, J. and Stiller, B. and Nagdyman, N. and Hubler, M. and Butrous, G. and Petros, A. and Lange, P. and Redington, A.N. (2003) Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation, 108 (10). pp. 167-173. ISSN 0009-7322.
|The full text of this publication is not available from this repository. (Contact us about this Publication)|
Background-Increased pulmonary vascular resistance (PVR) because of congenital heart disease (CHD) may be caused by a dysfunction in endogenous pulmonary endothelial nitric oxide (NO) production. In other forms of pulmonary vascular disease with increased PVR, an elevated activity of a phosphodiesterase type 5 (PDE-5), responsible for the degradation of cyclic guanidine monophosphate (cGMP), the second messenger of endothelially produced NO, has been demonstrated. This study compares the effects of inhaled NO before and after the specific inhibition of the PDE-5 by intravenous sildenafil (Viagra T) in pre- and postoperative children with increased PVR because of CHD.
|Additional information:||NOT IN FILE|
|Subjects:||R Medicine > R Medicine (General)|
|Divisions:||Faculties > Science Technology and Medical Studies > Kent Institute of Medicine and Health Sciences (KIMHS)|
|Depositing User:||M.P. Stone|
|Date Deposited:||12 Sep 2008 11:24|
|Last Modified:||12 Sep 2008 11:24|
|Resource URI:||http://kar.kent.ac.uk/id/eprint/12271 (The current URI for this page, for reference purposes)|
- Depositors only (login required):